ScaleReady and March Biosciences join forces to boost CAR-T cell therapy manufacturing, aiming for innovative treatments in critical hematologic malignancies.

ScaleReady, alongside Wilson Wolf and Bio-Techne, awards Moonlight Bio with a G-Rex Grant to enhance CAR T cell therapy development for solid tumors.

ScaleReady has awarded G-Rex Grants totaling nearly $2 million to multiple California institutions, boosting innovations in cell and gene therapy manufacturing. These awards support groundbreaking research and development efforts.

ScaleReady, along with its partners, has granted Sonoma Biotherapeutics $300,000 to fast-track the development of innovative Treg therapies for autoimmune diseases.

ScaleReady has awarded a $200,000 G-Rex® Grant to March Biosciences to advance the manufacturing of MB-105, a novel CAR-T cell therapy. The therapy targets CD5 for patients with T-cell lymphomas and received FDA orphan drug designation in January 2025. MB-105 is being developed for multiple CD5-positive blood cancers, including T-cell lymphoma, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma. The therapy's proprietary design allows it to target malignant cells while preserving normal T-cell function. The G-Rex Grant Program, which has awarded nearly 200 grants with over 50 new applications pending, provides up to $300,000 per recipient. Grant recipients gain access to ScaleReady's consortium of partners, offering expertise in: cGMP manufacturing Quality and regulatory affairs CGT business operations The program has been extended with millions in additional funding to continue supporting cell and gene therapy development.

ScaleReady (TECH) and partners awarded four G‑Rex Grants to Children's National Hospital totaling $375,000 to support translation of cell and gene therapies into the clinic.Grants: $100,000 to Dr. Patrick Hanley for a G‑Rex CAR‑T manufacturing process; $150,000 shared by Drs. Keller and Hanley to move VST and TAAT workflows into G‑Rex M series bioreactors; $75,000 to Dr. Amy Hont for ATTACK TAAT; $50,000 to Dr. Cruz for CAR‑modified TAAT process development.ScaleReady reports its G‑Rex Grant Program surpassed $40M of no‑cost product commitments and launched a free LEAN Cell & Gene event series.

ScaleReady announced that BrainChild Bio has received the G-Rex Grant to support research on a pediatric CAR-T therapy aimed at treating DIPG.

ScaleReady partners with major organizations to award a $300,000 G-Rex Grant to the Gates Institute, enhancing CAR T-cell manufacturing technology for better treatment solutions.

ScaleReady has awarded a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc., enhancing their capabilities in developing CAR-T cell therapies.

New G-Rex grant enables Qatar's Sidra Medicine to develop innovative CAR-T cell therapy for pediatric cancer. Program reaches $40M in commitments. Learn more.

Seattle Children's Therapeutics receives funding to enhance their CAR-T cell platform with cutting-edge G-Rex bioreactors and GMP-grade cytokines for clinical trials advancement.

$1.025M in G-Rex Grants awarded to advance innovative CAR-T cell therapy programs at USC and CHLA. Multiple cancer treatment breakthroughs in development. Learn more.

ST. PAUL, Minn., Aug. 14, 2025 /PRNewswire/ — ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant to develop …

New G-Rex grant supports 200 daily CAR-T treatments in India's first cell therapy facility. Discover how ScaleReady's $30M program transforms cancer treatment access. See impact.

University of Minnesota researchers receive grants for groundbreaking CAR-NK cell therapy, TIL therapy, and rare disease treatment development. See full details.

/PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that eight...

ScaleReady awards grant to advance BCB-276, a novel CAR-T treatment for incurable pediatric brain tumor DIPG, supporting Phase 2 trials and optimized manufacturing processes.

BioCytics has received a $100,000 G-Rex grant from ScaleReady to advance its innovative cell-based therapy for cancer treatment. This funding supports the development of immune cell manufacturing processes.

ScaleReady, alongside its partners, has awarded grants to enhance cell and gene therapy research at Children's National Hospital, advancing pediatric healthcare initiatives.